Features May 2013 Issue

Darbepoetin Alfa Not Advised for Anemic Heart Failure Patients

A recent study shows the popular medication didn’t improve the health of heart failure patients whose conditions are complicated by anemia.

A drug that commonly prescribed to treat anemia in heart failure patients may not improve the patients’ health or reduce the risk of death from heart failure, according to a study presented at the American College of Cardiology’s annual meeting in March. The study, conducted by researchers at the University of Gothenburg, Sweden, Cleveland Clinic and many other centers, found that patients who took the drug darbepoetin alfa experienced similar clinical outcomes as those who took a placebo. The study involved more than 2,000 anemic heart failure patients in 33 countries.

To continue reading this article you must be a paid subscriber.

Subscribe to Heart Advisor

Get the next year of HEART ADVISOR for just $20. That's a savings of $19 off the regular rate.

With your paid subscription you will receive unlimited access to all of our online content. That is over a decade of previous issues from Cleveland Clinic, the hospital rated #1 in cardiac care by U.S. News & World Report - free of charge.

Subscriber Log In

Forgot your password? Click Here.

Already subscribe but haven't registered for all the benefits of the website? Click here.